Dr. Nithin Karakala, MD

Dr. Karakala practices at UAMS Medical Center in Little Rock, Arkansas, part of University of Arkansas for Medical Sciences.

Dr. Karakala's NPI, 1639356827, was assigned on January 30, 2008. Dr. Karakala holds Arkansas license E-9397.

Dr. Karakala's primary practice is UAMS Medical Center, at 4301 West Markham Street Mail Slot 612, Little Rock, AR 72205 in Pulaski County. The practice phone is (501) 686-5000.

Dr. Karakala's primary practice is UAMS Medical Center in Little Rock, Arkansas, part of University of Arkansas for Medical Sciences. The medical group on file is UAMS - University of Arkansas for Medical Sciences. Dmand AI also links Dr. Karakala to 2 more dialysis centers and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Karakala practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Karakala's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Karakala's licenses on file in 2 states: Arkansas and Maryland.

CMS data shows 634 Medicare services from Dr. Karakala across 13 procedure codes in 2024, for 236 Medicare patients. Medicare paid $58,638 for them.

CMS counts 236 Medicare patients who saw Dr. Karakala in 2024. The largest group is 65 to 74, with 97 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 25% are also on Medicaid. Their average risk score is 4.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Karakala's median patient age at 67, with 54% women.

In 2024, Dr. Karakala wrote 442 Medicare Part D claims for 101 patients. 98% of them were for generic drugs. CMS names the drug for 376 of them, across 16 drugs with 11 or more claims each, at $8,322 in total drug cost. In 2023, CMS named 328 claims across 13 drugs.

Dr. Karakala accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Karakala as offering telehealth.

Dmand AI links 28 papers to Dr. Karakala, published from 2011 to 2025. 2018 was the busiest year, with 3. The most frequent topics are Acute Kidney Injury, Renal Dialysis and Renal Replacement Therapy. Dr. Karakala has published most often in Nephron. Dr. Karakala's most frequent co-authors are John M. Arthur, MD, Luis A. Juncos, MD and Andrew S. Allegretti, MD.

Dmand AI links Dr. Karakala to 1 clinical trial. Conditions studied include Shock, Septic and Acute Kidney Injury.

CMS Open Payments shows 16 general payments to Dr. Karakala from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 64% of the total. Otsuka America Pharmaceutical, Inc. paid the most, $382.